MedTrace Logo

Fluoxetine on Emotional Experience (FLEX) Study

NCT07424781 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-20

No results posted yet for this study

Summary

The goal of this clinical medicine study is to investigate how does antidepressant fluoxetine modulate anger processing in healthy young people . The main questions it aims is to answer are:

1. How does fluoxetine affect responses to anger-related stimuli such as words, faces, and autobiographical recall?
2. How does fluoxetine influence responses during frustration induction in frustrative non-reward and threat paradigms?
3. Does the effect manifest in physiological markers, including heart rate variability and facial expressions?

Researchers will compare fluoxetine to a placebo to see if drug fluoxetine affects anger processing.

Participants will:

Take 20mg fluoxetine or a placebo every day for 7 days. Visit the university site for questionnaire and tasks assessments. Heart rate variability and facial expressions will be recorded in some of the tasks.

Conditions

  • Depression - Major Depressive Disorder
  • Irritability
  • Depression

Interventions

DRUG

Fluoxetine

Participants will receive 20mg of fluoxetine daily for 7 days. Tablets encapsulated to aid blinding.

DRUG

Placebo

Participants will receive one dose placebo (sucrose) daily for 7 days. Tablets encapsulated to aid blinding.

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Oxford Health Biomedical Research Centre (OH BRC) support scheme

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07424781 on ClinicalTrials.gov